Literature DB >> 17083756

What should be our treatment goal in rheumatoid arthritis today?

J S Smolen1, D Aletaha.   

Abstract

Remission should be the treatment aim in management of rheumatoid arthritis (RA) today because joint damage may progress in RA patients with low disease activity but presumably does not progress in patients in clinical remission. However, stringent criteria are needed to define remission status, as some criteria in current use allow for considerable residual disease activity. Even using stringent criteria, remission is achievable in a sizable proportion of patients in clinical trials and practice. Defining remission requires an additional consideration: Should a patient who is receiving medication be regarded as in remission if disease is absent, or must the patient be off treatment to be considered to be in remission? A case is made for aiming for a definition of remission that includes patients who continue medication therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083756

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

1.  A Multistakeholder Approach to Improving Quality in Rheumatoid Arthritis: Proceedings from the Rheumatoid Arthritis Quality Expert Medical Panel.

Authors:  Jeffrey R Curtis; C Kent Kwoh; Albert J Rizzoli; John A Welz
Journal:  Am Health Drug Benefits       Date:  2014-11

2.  Radiographic quantifications of joint space narrowing progression by computer-based approach using temporal subtraction in rheumatoid wrist.

Authors:  Shota Ichikawa; Tamotsu Kamishima; Kenneth Sutherland; Takanobu Okubo; Kou Katayama
Journal:  Br J Radiol       Date:  2015-10-20       Impact factor: 3.039

Review 3.  Remission in juvenile idiopathic arthritis: current facts.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

4.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Arthritis Rheum       Date:  2011-03

Review 5.  Induction of remission in rheumatoid arthritis: criteria and opportunities.

Authors:  Guido Valesini; Manuela Di Franco; Francesca Romana Spinelli; Rossana Scrivo
Journal:  Rheumatol Int       Date:  2008-09-21       Impact factor: 3.580

6.  Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

Authors:  Gerd R Burmester; Eugen Feist; Matthew A Sleeman; Bing Wang; Barbara White; Fabio Magrini
Journal:  Ann Rheum Dis       Date:  2011-05-25       Impact factor: 19.103

7.  Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis.

Authors:  Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naoki Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Yoshiya Tanaka; Hisashi Yamanaka; Koichi Fujii; Takunari Yoshinaga; Bruce Freundlich; Michio Suzukawa
Journal:  Mod Rheumatol       Date:  2011-01-25       Impact factor: 3.023

Review 8.  Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials.

Authors:  Tsutomu Takeuchi; Nobuyuki Miyasaka; Shinichi Kawai; Naonobu Sugiyama; Hirotoshi Yuasa; Noriaki Yamashita; Noriko Sugiyama; Lorin Craig Wagerle; Bonnie Vlahos; Joseph Wajdula
Journal:  Mod Rheumatol       Date:  2014-05-20       Impact factor: 3.023

Review 9.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973

10.  Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.

Authors:  Helga Radner; Farideh Alasti; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2015-08-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.